Targeting PI3Kδ for lymphoma and immune diseases treatment: a review
Selective inhibitors targeting specific immune pathways show promise for lymphomas and autoimmune conditions.
This review surveys PI3Kδ-selective inhibitors for lymphoma and immune diseases, covering approved drugs and clinical trial candidates. It provides a useful drug development overview but lacks primary data.
What the study was
- Study design
- Narrative review
- Population
- Lymphoma and immune disease patients
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Molecular Diversity
Why it surfaced
Solid review of PI3Kδ inhibitors but limited novelty. Single-author review.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.